Last updated on November 2018

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma


Brief description of study

This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.

Clinical Study Identifier: NCT03448978

Find a site near you

Start Over

Virgina Cancer Specialists

Fairfax, VA United States
4.83miles
  Connect »

The Center for Cancer and Blood Disorders

Bethesda, MD United States
7.35miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.